SIRT5 regulation of ammonia-induced autophagy and mitophagy

Lucia Polletta, Enza Vernucci, Ilaria Carnevale, Tania Arcangeli, Dante Rotili, Silvia Palmerio, Clemens Steegborn, Theresa Nowak, Mike Schutkowski, Laura Pellegrini, Luigi Sansone, Lidia Villanova, Alessandra Runci, Bruna Pucci, Emanuela Morgante, Massimo Fini, Antonello Mai, Matteo A Russo, and Marco Tafani

Department of Experimental Medicine; University of Rome; Sapienza; Rome, Italy; Department of Drug Chemistry and Technologies; University of Rome; Sapienza, Rome, Italy; Department of Biochemistry; University of Bayreuth; Bayreuth, Germany; Institut für Biochemie & Biotechnologie; Martin-Luther-Universität Halle-Wittenberg; Halle, Germany; John A. Burns School of Medicine; University of Hawaii Cancer Center; University of Hawaii; Honolulu, HI USA; Department of Cellular and Molecular Pathology; IRCCS San Raffaele; Rome, Italy; Division of Endocrinology; Gerontology; and Metabolism; Department of Medicine; Stanford University; Stanford, CA USA; Pasteur Institute; Cenci Bolognetti Foundation; University of Rome; Sapienza, Rome, Italy

Keywords: ammonia, autophagy, glutaminase, glutamine, molecular rehabilitation, mitochondrial dynamics

Abbreviations: ACTB, actin, β; ATG, autophagy-related; BNIIP3, BCL2/adenovirus E1B 19kDa interacting protein 3; BPTES, bis-2-(5-phenylacetamido-1, 3, 4-thiadiazol-2-yl)ethyl sulfide; COX4I1, cytochrome c oxidase subunit IV isoform 1; CPS1, carbamoyl-phosphate synthase 1, mitochondrial; GABARAP, GABA(A) receptor-associated protein; GABARAPL2, GABA(A) receptor-associated protein-like 2; GLS, glutaminase; GLUD1, glutamate dehydrogenase 1; GLUL, glutamate-ammonia ligase; hexachlorophene, 2, 2'-methylenebis(3, 4, 6-trichlorophenol); MAP1LC3B, microtubule-associated protein 1 light chain 3 β; MFN2, mitofusin 2; OPA1, optic atrophy 1 (autosomal dominant); PARK2, parkin RBR E3 ubiquitin protein ligase; PEG, polyethylene glycol; PINK1, PTEN induced putative kinase 1; SIRT5, sirtuin 5; SQSTM1, sequestosome 1; TCA, tricarboxylic acid cycle; TEM, transmission electron microscopy.

In liver the mitochondrial sirtuin, SIRT5, controls ammonia detoxification by regulating CPS1, the first enzyme of the urea cycle. However, while SIRT5 is ubiquitously expressed, urea cycle and CPS1 are only present in the liver and, to a minor extent, in the kidney. To address the possibility that SIRT5 is involved in ammonia production also in nonliver cells, clones of human breast cancer cell lines MDA-MB-231 and mouse myoblast C2C12, overexpressing or silenced for SIRT5, were produced. Our results show that ammonia production increased in SIRT5-silenced and decreased in SIRT5-overexpressing cells. We also obtained the same ammonia increase when using a new specific inhibitor of SIRT5 called MC3482. SIRT5 regulates ammonia production by controlling glutamine metabolism. In fact, in the mitochondria, glutamine is transformed in glutamate by the enzyme glutaminase, a reaction producing ammonia. We found that SIRT5 and glutaminase coimmunoprecipitated and that SIRT5 inhibition resulted in an increased succinylation of glutaminase. We next determined that autophagy and mitophagy were increased by ammonia by measuring autophagic proteolysis of long-lived proteins, increase of autophagy markers MAP1LC3B, GABARAP, and GABARAPL2, mitophagy markers BNIIP3 and the PINK1-PARK2 system as well as mitochondrial morphology and dynamics. We observed that autophagy and mitophagy increased in SIRT5-silenced cells and in WT cells treated with MC3482 and decreased in SIRT5-overexpressing cells. Moreover, glutaminase inhibition or glutamine withdrawal completely prevented autophagy. In conclusion we propose that the role of SIRT5 in nonliver cells is to regulate ammonia production and ammonia-induced autophagy by regulating glutamine metabolism.

**Introduction**

Autophagy is a tightly regulated process used to remove cytosolic components or damaged organelles starting with the formation of double-membrane vesicles called autophagosomes. Subsequently, autophagosomes fuse and deliver their cargo to lysosomes for degradation and recycling. Initially thought of as a random process, autophagy is now regarded as an adaptive response specifically activated by stress or environmental changes.

From a molecular point of view, autophagy starts with the formation of a phagophore which requires the assembly of a protein complex composed of BECN1 (Beclin 1, autophagy-related), AMBRA1 (autophagy/Beclin 1 regulator 1), PIK3R4 (phosphoinositide-3-kinase, regulatory subunit 4) and PIK3C3 (phosphatidylinositol 3-kinase, catalytic subunit type 3), the catalytic
subunit of PtdIns3K. Subsequently, the phagophore membrane expands by the action of 2 ubiquitin-like conjugation protein systems: MAP1LC3B (microtubule-associated protein 1 light chain 3 β) and ATG12 (autophagy related 12)-ATG5 that assemble with ATG16L1 (autophagy related 16-like 1 [S. cerevisiae]) to promote cleavage and lipidation of MAP1LC3B by addition of phosphatidylethanolamine (PE). In this way MAP1LC3B-PE, also indicated as LC3-II, associates with the growing double-membrane structure until it closes forming the autophagosome that, as said, then fuses with a lysosome. A plethora of different stimuli can influence autophagy by regulating the proteins involved in autophagosome formation. In fact, nutrient starvation or rapamycin treatment can activate autophagy by inhibiting MTOR (mechanistic target of rapamycin [serine/threonine kinase]) thereby activating the ULK1 (unc-51 like autophagy activating kinase 1) and ULK2 proteins that, in turn, recruit other ATG proteins such as MAP1LC3B and ATG16L1 to the forming autophagosome.

Sirtuins (SIRT) are a family of NAD-dependent protein deacetylases and/or ADP ribosylases controlling metabolic homeostasis. Because of NAD dependency sirtuins are classified as class III histone deacetylase. Sirtuins have different intracellular localization being present in the nucleus (SIRT1 [sirtuin1] and SIRT6), nucleolus (SIRT7), cytosol (SIRT1 and SIRT2) and mitochondria (SIRT3, SIRT4, and SIRT5). Through post-translational modification of a growing number of nonhistonic proteins and enzymes, sirtuins have been shown to play a major role in many cellular aspects such as survival, aging, stress response, and metabolism. Similarly to autophagy-related genes, expression and activity of sirtuins are induced by stress and nutrients availability. A connection between sirtuins and autophagy has been suggested for SIRT1 and SIRT2. SIRT1 depletion in mammalian cells is accompanied by impaired or abolished autophagy. Moreover, SIRT1 coimmunoprecipitates with ATG5, ATG7, and LC3, and SIRT1-depleted mice have a phenotype very similar to that of atg5-KO mice. Considering that SIRT1 is both cytosolic and nuclear, it has been suggested that SIRT1 could regulate autophagy by deacetylating autophagy proteins or, alternatively, by regulating the binding of transcription factors to promoter regions of autophagy genes.

Overexpression or pharmacological activation of SIRT1 induced autophagy both in vitro and in vivo. In particular, SIRT1-induced autophagy reduced prion- and ischemia-induced neurotoxicity, increased remodeling in postinfarction heart improving cardiac function and, reduced endothelial inflammation after TNF treatment. Finally, also the longevity effects of caloric restriction and resveratrol treatment in C. elegans have been linked to the activation of autophagy by SIRT1.

In the case of SIRT2, instead, it seems that during prolonged periods of stress, this sirtuin dissociates from FOXO1 (forkhead box O1) an effect that results in hyperacetylation of the latter. Hyperacetylated FOXO1 then binds to ATG7 promoting autophagy. In fact, SIRT2 inhibition or downregulation is accompanied by increased autophagy in human neuroblastoma cells in the presence of proteasome inhibition. By contrast, SIRT2 inhibition triggers necrosis and not autophagy in mouse Schwann cells. Therefore, even if SIRT2 may represent a good candidate for treatment of neurodegenerative disorders, more work is needed to understand its mechanism of action.

No links between autophagy and other sirtuins have been observed. However, the mitochondrial sirtuin, SIRT5, has been implicated in the control of ammonia levels by deacetylating and activating CPS1 (carbamoyl-phosphate synthase 1, mitochondrial), the rate-limiting enzyme of the urea cycle. In fact, SIRT5-deficient mice have 30% lower CPS1 activity and show hyper ammonia under fasting conditions. Additionally, recent studies have shown that SIRT5 is a NAD-dependent protein lysine demalonylase, desuccinylase, and deglutarylase even of the described deacetylase target CPS1. In particular, it seems that SIRT5 has a strong demalonylation, desuccinylating, and deglutarylating activity and a weak deacetylating activity. SIRT5 is a global regulator of lysine succinylation in mitochondria and, in fact, MEF from Sirt5-deficient mice show a significant increase in Lys succinylation. In the case of CPS1, its activity was reduced in Sirt5-deficient mice due to an increased succinylation and not acetylation. Interestingly, SIRT5 lysine desuccinylating seems to impact enzymes involved in diverse mitochondrial metabolic pathways and to inhibit biochemical activity and mitochondrial respiration by suppressing the activity of the pyruvate dehydrogenase complex and succinate dehydrogenase. From these initial studies it is clear that: i) SIRT5 possesses different post-translational modification activities and ii) SIRT5 influences ammonia levels by regulating CPS1 activity and urea cycle.

Recently, ammonia has been shown to induce autophagy in tumor cells via a paracrine and autocrine stimulation. Moreover, ammonia-induced autophagy is independent from MTOR and ULK1/2. From these considerations we reasoned that SIRT5 could be linked to ammonia-induced autophagy. So far SIRT5 has been shown only to regulate the urea cycle that takes place exclusively in the liver and, to a minor extent, in the kidney. However, SIRT5 is ubiquitously expressed in various tissues. Therefore, SIRT5 may probably have other substrates besides CPS1. In addition, it is possible that the metabolic pathway(s) regulated by SIRT5 in other tissues, are still those involved in the regulation of ammonia. Glutamine has an important role in the anaplerosis of the Krebs cycle and glutaminolysis is an important source of cellular ammonia. Mitochondrial GLS (glutaminase) is the first enzyme in glutaminolysis. To date, 3 mammalian GLSs have been identified: GLS2 (glutaminase 2 [liver, mitochondrial]), GLSK (glutaminase kidney-isoform, mitochondrial) and GLSC/glutaminase C a splice variant of GLS (both usually referred to as GLS). Human GLS consists of 669 amino acids and is structured in a short mitochondrial signaling peptide, a nuclear receptor box, glutaminase domain (cGLS), 3 ankyrin repeats, and APC/C-Cdh1 specific recognition motif (KEN box). Interestingly, the catalytic domain of GLS is exposed in the mitochondrial matrix and GLS(K) is often overexpressed in tumors. Our hypothesis is that SIRT5 could control ammonia levels by regulating glutaminase and glutamine metabolism and, in particular, by regulating the activity of CPS1. The described deacetylase target CPS1.
Ammonia levels are increased in SIRT5-silenced and reduced in SIRT5-overexpressing cells

Urea cycle and ammonia levels are regulated by SIRT5 through deacetylation and desuccinylation of CPS1.23-25 However, urea cycle takes place in the liver whereas SIRT5 is ubiquitously expressed.23 What is the role of SIRT5 in other tissues? Is it always involved in the regulation of ammonia levels? To answer these questions, we obtained SIRT5-overexpressing or silenced MDA-MB-231 and C2C12 cellular clones (upper inserts in Fig. 1A). Desuccinylating activity was measured in WT, SIRT5-overexpressing or SIRT5-silenced clones. We observed that, compared to WT cells, SIRT5-overexpressing cells had an increased desuccinylating activity that was significantly reduced in SIRT5-silenced cells (Fig. 1A). In addition we also treated WT cells with a newly synthesized specific SIRT5 inhibitor called MC3482. This inhibitor was synthesized as described in the supplementary text. The MC3482 effects on MDA-MB-231 and C2C12 cells are shown in Figure 1A. 50 μM MC3482 inhibits SIRT5 desuccinylating activity without affecting SIRT5 intracellular expression levels (lower inserts in Fig. 1A). The extent of inhibition of SIRT5 by MC3482 was tested by treating MDA-MB-231 cells with a different concentration of this compound and using a commercially available desuccinylating kit for SIRT5. Figure S1 shows how SIRT5 inhibition increases when treating cells with increasing concentration of MC3482. In particular a 42% inhibition was achieved when using 50 μM MC3482. The specificity of MC3482 for SIRT5 was determined by assessing the activity of other sirtuins. Figure S2 shows that the activity of the nuclear sirtuin SIRT1 was not significantly inhibited by 50 μM MC3482. Similarly, only an 8% inhibition of the mitochondrial sirtuin SIRT3 was observed in the presence of 50 μM MC3482. Therefore, in order to avoid excessive SIRT3 inhibition by MC3482, we decided to use a 50-μM concentration throughout the experiments.

Protein desuccinylation was also measured with a monoclonal anti-succinyl lysine antibody on whole cellular extracts. Figure 1B shows that, compared to control WT cells, SIRT5-silenced cells and WT cells treated with the SIRT5 inhibitor MC3482 had an increase in succinylated proteins. By contrast SIRT5-overexpressing cells showed a lower succinylation (Fig. 1B). We also measured acetylation through an anti-acetyl lysine antibody. In this case, we could not detect a significant change in whole protein acetylation between WT, WT plus MC3482, and SIRT5-overexpressing or silenced cells (Fig. 1B).

To study SIRT5 involvement in the regulation of ammonia levels, we measured ammonia released in growth medium in our WT and SIRT5 clones. We observed that SIRT5 overexpression reduced ammonia accumulation in culture medium (Fig. 1C). By contrast, SIRT5 silencing significantly increased ammonia accumulation compared to WT cells (Fig. 1C). Again an ammonia increase was also observed when treating cells with the SIRT5 inhibitor MC3482 (Fig. 1C). Importantly, when using SIRT3-overexpressing and silenced MDA-MB-231 or C2C12 cells we did not observe any significant ammonia variation compared to WT cells (Fig. 1C).

SIRT5 regulates glutamine metabolism

Glutamine is classified as a nonessential amino acid that, however, represents an important nitrogen source.38 In particular, glutamine acts as precursor of glutamate and ammonia and has therefore an important role in the brain and other tissues.39,40 Glutamine metabolism is accelerated in tumor cells as well as in rapidly proliferating nontumor cells.31,42 This metabolism mainly occurs in the mitochondria where glutamine is converted to glutamate and ammonia by the enzyme GLS.36,43 The opposite reaction that from glutamate and ammonia generates glutamine, is performed by the enzyme GLUL (glutamate-ammonia ligase).44 In order to understand if SIRT5 can regulate these 2 enzymes, expression levels of GLUL and GLS were measured in MDA-MB-231. Figure 2A shows that, in SIRT5-silenced cells GLS levels were increased compared to WT and SIRT5-overexpressing cells. We focused our attention on GLS because this enzyme, contrary to GLUL, has a mitochondrial localization and, in addition, its functionally relevant domain faces the mitochondrial matrix where SIRT5 resides.36 Therefore, to investigate a possible endogenous interaction between SIRT5 and GLS, we performed immunoprecipitation assays. Our results show that SIRT5 coimmunoprecipitates with GLS (Fig. 2B). We used WT cells treated with SIRT5 inhibitor and not SIRT5-silenced cells in our immunoprecipitation experiments because we encountered some problems to interpret the results probably due to the increased GLS expression present in the latter (see Fig. 2A). In fact, when we used the SIRT5 inhibitor, we observed a decreased association between GLS and SIRT5 (Fig. 2B). Interestingly, in these same samples treated with the SIRT5 inhibitor, we instead observed an increased succinylation of a protein(s) with a molecular weight similar to that of GLS as shown in figure 2B. To confirm this result, we immunoprecipitated WT cells, either left untreated or treated with MC3482, as well as SIRT5 clones with a SIRT5 antibody and then immunoblotted for GLS. Figure 2C shows, again, a coimmunoprecipitation between SIRT5 and GLS. Importantly, we observed a lower SIRT5-GLS interaction in SIRT5-silenced clones. By contrast, GLS succinylation decreased in SIRT5-overexpressing cells and increased in SIRT5-silenced or WT cells treated with MC3482 (Fig. 2C).

To confirm that SIRT5 may control GLS activity through its desuccinylation, we measured glutamate accumulation in MDA-MB-231 and C2C12 WT cells and SIRT5 clones. We also used
the GLS inhibitor BPTES and, again, measured glutamate and ammonia accumulation. Figure 3A shows that glutamate levels decreased in SIRT5-overexpressing cells and increased in SIRT5-silenced cells and in WT cells treated with MC3482. Importantly, glutamate accumulation was reduced to the same extent in WT cells as well as in SIRT5 clones by the addition of BPTES (Fig. 3A). Similarly, BPTES inhibited ammonia accumulation in MDA-MB-231 and C2C12 cells as did the treatment with dimethyl-α-ketoglutarate that works by replenishing the anaplerotic flux (Fig. 3B).

Glutamate produced during glutaminolysis is converted to α-ketoglutarate by the mitochondrial enzyme GLUD1 (glutamate dehydrogenase 1) with production of ammonia.\(^4\) Therefore, to investigate the possibility that SIRT5 could control ammonia production by regulating also GLUD1 activity we performed immunoprecipitation assays. As shown in Figure S3A, we did not observe a coimmunoprecipitation between GLUD1 and SIRT5, whereas we confirmed a GLUD1-SIRT3 coimmunoprecipitation (Fig. S3A). In addition, we did not observe any difference in GLUD1 activity in WT and SIRT5 clones of MDA-MB-231 cells (Fig. S3B). However, both GLUD1 inhibitors that we tested, hexachlorophene and dimethyl-α-ketoglutarate, significantly reduced GLUD1 activity in WT cells and SIRT5 clones (Fig. S3B). Finally, the central role of glutamine for ammonia production in our system, was determined by culturing cells in the absence of glutamine for several days. As shown in Figure S4, glutamine withdrawal lowered ammonia produced by both MDA-MB-231 and C2C12 cell lines. Moreover, after glutamine withdrawal,
Ammonia-induced autophagy is regulated by SIRT5

Considering our immunoprecipitation results, SIRT5-GLS docking analysis and the recent reports suggesting that ammonia derived from glutaminolysis induces autophagy through an MTOR independent-ATG dependent mechanism, we investigated if ammonia released in SIRT5 clones or cells treated with SIRT5 inhibitor, could induce autophagy. Autophagy induction was initially investigated by TEM. Figure 4 shows that in SIRT5-silenced (Fig. 4D) and in WT MDA-MB-231 cells treated with MC3482 (Fig. 4C), there is an accumulation of...
autophagosomes and autolysosomes some of them in the process of fusion (Fig. 4C and D). Subsequently, we also determined levels of autophagic markers MAP1LC3B, GABARAP (GABA[A] receptor-associated protein) and GABARAPL2 (GABA[A] receptor-associated protein-like 2). MDA-MB-231 cells silenced for SIRT5 showed increased LC3-II levels compared to WT cells (Fig. 5A). Again, a similar LC3-II increase was present in WT cells treated with SIRT5 inhibitor (Fig. 5A). By contrast, SIRT5 overexpression resulted in the absence of LC3-II (Fig. 5A).

LC3-II accumulation was also measured by immunofluorescence. Figure S8A shows that, compared to WT or SIRT5-overexpressing cells, LC3-II accumulated in SIRT5-silenced cells and in WT cells treated with MC3482. Such an accumulation was also clear after 4 d of culture as reported in Figure S8B. In order to exclude that the lack of LC3-II signal in SIRT5-overexpressing cells was due to increased autophagic flux, we treated WT and SIRT5 clones with bafilomycinA1 for 2 and 17 h. As shown in Figure 5A, LC3-II levels in SIRT5-overexpressing cells treated with bafilomycinA1 were similar to LC3-II levels of bafilomycinA1-treated WT cells, whereas SIRT5-silenced clones had an increased accumulation of LC3-II after 2 and 17 h. This result suggests that LC3-II absence in SIRT5-overexpressing cells is due to reduced autophagy induction and not to an increased autophagic flux as also shown in TEM pictures of Figure 4B. Ammonia-induced autophagy was a characteristic of SIRT5 clones since LC3-II levels were not increased in MDA-MB-231 cells overexpressing or silenced for another mitochondrial sirtuin, SIRT3 (Fig. 5A). We also measured expression of LC3 paralogs GABARAP and GABARAPL2 that, sometimes, can be better indicators of autophagy.52 In MDA-MB-231 cells, GABARAPL2 processing and GABARAP accumulation was observed only in SIRT5-silenced clones and in WT cells treated with the SIRT5 inhibitor (Fig. 5A). We also determined SQSTM1 (sequestosome 1) levels as a marker of lysosome degradation of the autophagosome cargo. Figure 5B, shows that SQSTM1 degradation was impaired in SIRT5-overexpressing cells but not in SIRT5-silenced cells or in WT cells treated with SIRT5 inhibitor and that bafilomycinA1 treatment prevented SQSTM1 degradation in SIRT5-silenced cells and in WT cells treated with MC3482 (Fig. 5B). To demonstrate that ammonia can increase accumulation of autophagic markers, we treated MDA-MB-231 cells with exogenous ammonia at a concentration similar to those reached in the cell medium after 4 d of culture. As shown in Figure 5C, ammonia at 2 mM concentration induced autophagy as demonstrated by accumulation of LC3-II, GABARAPL2, GABARAP, and SQSTM1 degradation. Similarly, Figure S8 shows LC3 puncta accumulation by
immunofluorescence in NH₄Cl treated cells. Ammonia production derives from glutaminolysis since, as shown in Figure 5D, treatment of cells with GLS inhibitor BPTES or dimethyl-α-ketoglutarate, completely prevented LC3-II, GABARAPL2 accumulation as well as SQSTM1 degradation. Importantly, accumulation of LC3-II and degradation of SQSTM1 were prevented by L-glutamine withdrawal (Fig. 5E). It must be noted that prolonged glutamine withdrawal was accompanied by significant cell death (not shown).

Similar results were obtained in C2C12 cells where SIRT5 silencing as well as SIRT5 pharmacological inhibition and ammonia supplementation, increased LC3-II, GABARAPL2, and GABARAP levels (Fig. 5F).

Autophagic proteolysis was measured by labeling long-lived proteins by the Click-iT AHA method as described in Materials and Methods. In fact, AHA is a surrogate for L-methionine with an azide group that is incorporated into proteins during protein synthesis. In particular, cells can be pulsed with AHA to label long-lived proteins followed by a short incubation in medium without AHA to chase out short-lived proteins. At this point the Click reaction allows the binding of a fluorescent alkyne group to the azide. In this way increased autophagy will result in a reduction of fluorescent long-lived proteins. By contrast, inhibition of autophagy or inhibition of lysosome proton pump activity, as in the case of bafilomycinA₁ treatment, will increase the signal from fluorescent long-lived proteins. Our results are shown in Figure 6. Confocal analysis of autophagic proteolysis showed a decrease in fluorescence in WT MDA-MB-231 cells treated for 3 h with 2 mM NH₄Cl or with 50 μM MC3482. By contrast no decrease was observed in cells treated with 10 mM NH₄Cl. Importantly, 10 mM NH₄Cl also prevented starvation-induced autophagic proteolysis in WT cells (Fig. 6A). These results were quantified by reading the fluorescence intensity in a fluorimeter as reported in Figure 6B. Fluorescence from long-lived proteins decreased by about 15% in MDA-MB-231 WT cells treated with 2 mM NH₄Cl or with MC3482 for 3 h. Interestingly, treatment of MDA-MB-231 WT cells with 10 mM NH₄Cl did not increase autophagic proteolysis but prevented starvation-induced protein degradation. Similar results were obtained in C2C12 cells although we had to prolong treatments up to 6 h (Fig. 6B right panel).

Mitophagy regulation by SIRT5

Our results indicates that SIRT5 controls glutamine metabolism and the consequent ammonia-induced autophagy. We next investigated if ammonia regulation by SIRT5 could also influence the selective degradation of mitochondria through so-called mitophagy. In fact, mitophagy is a tightly regulated process that selectively sequesters and degrades superfluous, damaged, or potentially dysfunctional mitochondria representing, as in the case of autophagy, both a cell death and a survival process.5,52 Induction of mitophagy, in our system, was assessed by measuring different markers and precisely, BNIP3 (BCL2/adenovirus E1B 19kDa interacting protein 3) and the PINK1 (PTEN induced putative kinase 1) and PARK2 (parkin RBR E3 ubiquitin protein ligase) system. BNIP3 is a autophagy receptor on the mitochondria that interacts with MAP1LC3B and GABARAP committing dysfunctional mitochondria to mitophagy.5,52,53 Our results show that in SIRT5-silenced MDA-MB-231 cells as well as in WT cells treated with the SIRT5 inhibitor MC3482, there is an increase of BNIP3 in the mitochondria whereas a decrease was observed in SIRT5-overexpressing cells (Fig. 7A).
**Figure 5.** For figure legend see page 261.
Interestingly, when cells were treated with bafilomycinA₁, we observed a BNIP3 increase that was, however, more marked in SIRT5-silenced cells. The central role of GLS-dependent glutaminolysis with ammonia accumulation for mitophagy was demonstrated by treating cells with BPTES, dimethyl-α-ketoglutarate, NH₄Cl and glutamine withdrawal (Fig. 7A). In fact, BPTES, dimethyl-α-ketoglutarate and glutamine withdrawal completely inhibited BNIP3 accumulation whereas, ammonia supplementation increased BNIP3 levels in the cells. This result suggests that the mitochondrial degradation following association between the autophagy receptor BNIP3 on the mitochondria and the autophagy marker MAP1LC3B is reduced after SIRT5 overexpression and increased after SIRT5 silencing or inhibition.

The PINK1-PARK2 pathway is another system to control mitophagy.⁵⁵⁻⁵⁷ In particular, PINK1 accumulates in the mitochondria thereby recruiting PARK2 through an unknown mechanism. PARK2, in turn, ubiquitinates mitochondrial proteins (mitochondria) thereby recruiting PARK2 through an unknown mechanism. PARK2 on the mitochondria.⁵⁷ MFN2 ubiquitination and degradation serves, then, as a signal for mitophagy.⁵⁷ Figure 7A shows that both PINK1 and PARK2 accumulate in mitochondrial fractions of SIRT5-silenced cells, in WT cells treated with MC3482 as well as in WT cells treated with NH₄Cl. By contrast, PINK1 and PARK2 levels decreased in SIRT5-overexpressing cells. MFN2 (mitofusin 2) is one of the few substrates that is ubiquitinated by PARK2 on the mitochondria.⁵⁷ MFN2 ubiquitination and degradation serves, then, as a signal for mitophagy.⁵⁷ As shown in Figure 7A, MFN2 levels decreased in both SIRT5-silenced and WT cells treated with SIRT5 inhibitor. Interestingly, we also observed that OPA1 (optic atrophy 1 [autosomal dominant]), another protein of the mitochondrial fusion machinery, was increased in SIRT5-overexpressing cells and decreased when SIRT5 was silenced or inhibited (Fig. 7A).

Similar results were obtained in C2C12 cells. Figure 7B shows an increase in BNIP3 in SIRT5-silenced cells, in WT cells treated with MC3482 or with NH₄Cl. We also observed a decrease in MFN2 and OPA1 in SIRT5-silenced cells and in WT cells after SIRT5 inhibition, whereas BNIP3 decreased and MFN2 levels increased in SIRT5-overexpressing cells.

SIRT5 influences mitochondrial dynamics

Glutamine homeostasis influences mitochondrial dynamics suggesting that the energetic status of the cell and mitochondrial morphology are somehow interlinked.⁵⁷⁻⁵⁹ Moreover, increased MFN2 and OPA1 levels that we observed, could alter mitochondrial dynamics favoring mitochondrial fusion. In addition, mitochondrial membrane potential is influenced by the organelle’s morphology with higher potential in large fused mitochondria.⁵⁹ We therefore measured mitochondrial morphology and potential in SIRT5-overexpressing and silenced cells. Figure 8A shows that SIRT5-overexpressing MDA-MB-231 and C2C12 cells had a greater number of mitochondria with a red JC-1 staining indicating higher mitochondrial membrane potential. Almost no red mitochondria were present in SIRT5-silenced cells and in WT cells treated with MC3482 or with NH₄Cl (Fig. 8A). Additionally, JC-1 mitochondrial staining showed that SIRT5-overexpressing cells had large elongated mitochondria well distributed along the cellular processes whereas, SIRT5-silenced cells as well as WT cells treated with MC3482 or NH₄Cl had small round mitochondria clustered around the nucleus (Fig. 8A). ATP levels and lactate production were measured in our cells. Figure 8B shows that ATP levels were similar in WT cells and in SIRT5 clones. Addition of 2-deoxy-D-glucose (2DG), an inhibitor of glycolysis, reduced ATP levels in WT as well as in SIRT5 clones (Fig. 8B). However, reduction of ATP levels was more significant in SIRT5-silenced cells and in WT cells treated with MC3482 (Fig. 8B). Importantly, lactate production was decreased in SIRT5-overexpressing cells and increased in SIRT5-silenced or in WT cells after SIRT5 inhibition (Fig. 8B).
The presence of large fused mitochondria in SIRT5-overexpressing cells and the increase in the fusion proteins MFN2 and OPA1 prompted us to investigate if this was due to a shift of mitochondrial dynamics in favor of fusion. Fusion of the mitochondria was studied by the PEG fusion assay as indicated in Materials and Methods. Figure 9 shows that, compared to WT C2C12 cells, SIRT5-silenced cells had a lower number of fused yellow mitochondria whereas SIRT5-overexpressing cells had a higher number of fused yellow mitochondria as well as mitochondria with red or green extremities and yellow center as indicated by the arrows.

Discussion

In the present study we demonstrate that SIRT5 regulates ammonia production by influencing glutamine metabolism through the binding and desuccinylation of GLS. Ammonia increases autophagy in a paracrine and autocrine fashion. SIRT5 overexpression reduces ammonia accumulation whereas, SIRT5-silencing or inhibition increases ammonia production and ammonia-induced autophagy. Finally, SIRT5 also regulates mitochondrial dynamics and mitophagy probably by controlling glutamine metabolism and ammonia accumulation.

Glutamine is the most abundant nonessential amino acid and serves as a storage form of glutamate and ammonia. Glutamine is important for anaplerosis of the Krebs cycle. Therefore, in tumor cells, where glucose is mainly used through glycolysis, glutamine metabolism is accelerated and glutamine represents an important source of energy. GLS is the main enzyme for glutaminolysis and catalyzes the transformation of glutamine in glutamate and ammonia. GLS resides in the mitochondria and its functionally relevant domain faces the mitochondrial matrix. Interestingly, tumor cells show a higher GLS activity and expression than normal cells. Therefore, in growing tumors, glutamine addiction and utilization releases ammonia that is then used by surrounding tumor cells to increase autophagy and autophagic removal of toxic by-products.
effect, our results show that GLS expression increases in SIRT5-silenced cells (Fig. 2A) with a corresponding increased accumulation of ammonia and autophagy induction. The central role of GLS for ammonia production is demonstrated by the fact that BPTES, a GLS inhibitor, completely prevents ammonia accumulation as well as autophagy induction (Figs. 3 and 5B). Similarly, autophagy was induced by adding ammonia to the culture medium at a concentration equivalent to that reached after 4 d of culture. Importantly, the increase of autophagic markers observed when ammonia was added to the cells was accompanied by an increase of autophagic proteolysis of long-lived protein demonstrating the presence of a correct lysosomal activity (Fig. 6).

It is worth noting that SIRT5 is downregulated in tumors63 and that in our hands, a newly specific SIRT5 inhibitor reproduced the same increase of ammonia production and autophagy and mitophagy induction as SIRT5-silencing. Our results also show a coimmunoprecipitation between SIRT5 and GLS (Fig. 2B and C) that was reduced after pharmacological inhibition of SIRT5. In addition, SIRT5 inhibition resulted in an increased succinylation of GLS (Fig. 2B and C). Moreover, glutamate production is reduced in SIRT5-overexpressing cells and increased in SIRT5-silenced or in WT cells treated with
MC3482 demonstrating a regulation of GLS activity (Fig. 3A). To this regard, it is worth noting that recently, Park et al. have shown that SIRT5 has structural preferences for its enzymatic activity. In particular, motif analysis identified AK, GK, KF and KA motifs as significantly overrepresented for Lys succinylation sites. A screening analysis identified, among a total of about 800 proteins, GLS as a putative succinylated substrate. In particular Lys 253 of mouse GLS2 was identified as a putative succinylation site. According to this, our docking protein-protein analysis of human GLS and SIRT5 suggests that: i) SIRT5 fits in the cavity of a tetramer of GLS; ii) Lys 320, that corresponds to the mouse 253, and also Lys 245 are on opposite sides of the GLS active site; iii) these 2 lysines may be accessible to the SIRT5 catalytic pocket; iii) these 2 lysines and the amino acids at position −1 and +1 are highly conserved among different species (Fig. S5 to S7).

Our results also demonstrate that SIRT5 regulates mitophagy and mitochondrial dynamics. In fact, we showed that the mitophagy markers BNIP3 and PINK1-PARK2 system are reduced in SIRT5-overexpressing and increased in SIRT5-silenced cells or in WT cells treated with a SIRT5 inhibitor. Again these biological effects of SIRT5 manipulation are due to the control of glutamine metabolism and ammonia-induced autophagy by SIRT5. In fact, inhibition of GLS with BPTES, inhibition of anaplerosis with dimethyl-α-ketoglutarate and, L-glutamine withdrawal reduced mitophagy marker BNIP3 (Fig. 7). By contrast, ammonia supplementation increased mitophagy by accumulating BNIP3, PINK1, and PARK2 (Fig. 7). Our results suggest that SIRT5 downregulation observed in tumors can activate the protective effects of ammonia-induced autophagy toward stressful conditions such as for example hypoxia or chemotherapy. Activation of mitophagy observed in SIRT5-silenced cells is probably due to the loss of membrane potential and to the reduced size of mitochondria observed in these cells and may, again, represent a protective mechanism for these cells by removing damaged and dysfunctional mitochondria that could, for example, produce high levels of toxic products. All these effects are absent when SIRT5 is present or overexpressed. In this case, we observed mitochondria with elongated shape, widely distributed in the cells and, with high membrane potential (Fig. 8A). Mitochondria from SIRT5-silenced cells or cells treated with a SIRT5 inhibitor, also show a decrease of ATP content when
treated with the glycolysis inhibitor 2DG and increased lactate production. However, the drop of extracellular pH was from 7.4 to 6.7 in WT cells as well as in SIRT5 clones. One possible explanation is that glutamate produced by GLS is further oxidized to yield CO$_2$ and HCO$_3^-$, bicarbonate accumulation can, in turn, buffer protons in culture medium. Therefore, the situation could be similar to that reported by Atkinson and Bourke$^{64}$ to explain how metabolic acidosis can be counteracted by increasing GLS activity in the kidney, an event that generates bicarbonate that, in turn, prevents the drop of systemic pH$^{64}$. In the case of SIRT5-silenced cells, increased GLS activity, herewith documented, would determine an increase glutamate accumulation and oxidation to generate bicarbonate that, in turn, can buffer excess of protons and reduce pH drop.

We also documented a decreased probability of mitophagy induction as testified by lower expression of BNIP3 as well as PINK1 and PARK2 (Fig. 7A and B). The increased mitochondrial size in SIRT5-overexpressing cells was also due to accumulation of fusion proteins MFN2 and OPA1, an event, that, at least for MFN2 was probably due to the reduction of PINK1-PARK2 system that, when accumulating on the mitochondrial membrane, ubiquitinates MFN2 activating the mitophagic process. Therefore, we show that, by controlling glutamine metabolism, SIRT5 also controls 2 interlinked processes such as autophagy and mitophagy.

Recently a metabolic characterization of a Sirt5-deficient mouse model has been reported. Interestingly, sirt5 KO mice have elevated ammonia blood levels after 24 h fasting, but do not show any metabolic change compared to WT mice under basal conditions. These results raise the question about the importance of Sirt5 for metabolic homeostasis. However, as in the case of sirt3 KO mice, it may be necessary to increase or prolong the stress to observe a metabolic difference between sirt5 KO and Sirt5 WT mice. Moreover, the observation of a prenatal loss of 40% of sirt5 KO offspring is particularly interesting for 2 reasons: i) it may be related to an imbalance in glutamine metabolism and autophagy that would result in embryonic malformations and death; ii) it may be that the surviving offspring are born because were able to bypass the metabolic imbalance, due to Sirt5 absence, by increasing the activity or expression of other sirtuins or mitochondrial enzymes. In fact, as also suggested by Yu et al., mitochondrial sirtuins may be involved in sensing and removal of erroneous acyl modifications in proteins. These would be the reasons why it may be necessary to prolong the stress on sirt5 KO mice in order to observe metabolic changes. Finally, it would be interesting to measure glutamine metabolism in sirt5 KO mice as well as behavioral abnormalities under prolonged fasting that may be caused by increased damage to the brain because of excessive ammonia.

Another interesting aspect is that our results are in agreement and complete those recently published by Csibi et al., in which the authors report that the CRTC1 (CREB-regulated transcription coactivator 1) pathway increases glutamine metabolism by removing SIRT4 inhibition on GLUD1. In fact, GLUD1 is the enzyme that, in glutaminolysis, follows the GLS catalysis of the reaction that transforms glutamate in $\alpha$-ketoglutarate with ammonia release. Studies show that SIRT4 is downregulated in human cancer and that SIRT4 overexpression reduces tumor formation, however, they do not report ammonia levels in the absence or overexpression of SIRT4 and autophagy induction.

Based on their and our results, we can predict that both SIRT5 and SIRT4 controls the 2 sequential steps of glutamine metabolism. SIRT5 would inhibit GLS activity and transformation of glutamine to glutamate with ammonia production whereas,

![Figure 9. Mitochondrial fusion in WT cells and in SIRT5 clones. Two separate populations of C2C12 WT, or SIRT5$^-$ or SIRT5$^+$ cells were incubated with either MitoTrackerGreen or MitoTrackerRed. Subsequently the 2 populations were cocultured in the presence of PEG to stimulate cellular fusion as described under Materials and Methods. Cells with green-labeled mitochondria fused with cells with red-labeled mitochondria were analyzed under confocal microscope (LSM510 Zeiss). The presence of mitochondria fusion was assessed by the appearance of yellow mitochondria. Pictures on the right side are enlargements of the images in the white box on the left. White arrows in the lower right panel indicate the presence of large fused or fusing mitochondria. Pictures of mitochondria were taken at 60x with a LSM510 Zeiss Confocal Microscope.](www.tandfonline.com)
SIRT4 would inhibit GLUD1 activity and transformation of glutamate to α-ketoglutarate with, again, ammonia production. However, in our experiments we could not detect an interaction, through immunoprecipitation, between SIRT5 with GLUD1 whereas we were able to observe a GLUD1-SIRT3 coimmunoprecipitation (Fig. S3). Therefore, both SIRT4 and SIRT5 would regulate glutamine homeostasis and ammonia levels. It is also interesting to notice that SIRT5 and SIRT4 inhibitory effects are achieved by 2 different post-translational modifications, that is: desuccinylation and ADP-ribosylation, respectively. According to us this allows for a tighter control of an important metabolic pathway such as glutamine homeostasis. Finally, additionally the other mitochondrial sirtuin SIRT3 controls glutamine homeostasis by deacetylating and activating GLUD1 to regulate the TCA cycle. Therefore, glutamine homeostasis may represent the first example of a pathway regulated by all 3 mitochondrial sirtuins and for this reason is an important metabolic target.

A schematic representation of our findings explaining the central role of SIRT5 in controlling ammonia-induced autophagy and mitophagy is drawn in Figure 10. SIRT5 by inhibiting the activity of GLS reduces ammonia released in the presence of glutamine. Ammonia reduction is accompanied by a reduction of ammonia-induced autophagy and mitophagy as measured by the markers listed in the figure.

Our new findings on the role of SIRT5 in glutamine metabolism are important because of potential implication in numerous human pathologies such as tumor development, neurodegenerative diseases, hepatic encephalopathy, etc. that are due to blood ammonia accumulation. In fact, one could foresee that SIRT5 activation would result in a decrease of ammonia produced in the presence of glutamine. In the case of tumor development, ammonia-induced autophagy has been regarded as a protective mechanism for tumor cells. Therefore, SIRT5 activation would reduce ammonia-induced autophagy reducing also the ability of tumor cells to survive to chemotherapy or other stresses such as hypoxia or nutrient starvation. In the case of pathologies related to ammonia accumulation, SIRT5 activation could be beneficial for reducing damage to cells sensitive to ammonia accumulation such as astrocytes.

**Materials and Methods**

**Cell culture**

The MDA-MB-231 human breast carcinoma cell line and the C2C12 mouse myoblast cell line were purchased from LGC Standards (HTB-26 and CRL-1772, respectively). MDA-MB-231 were maintained in RPMI 1640 medium (Sigma-Aldrich, R0883), C2C12 were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich, D65446). Both mediums were supplemented with 1% penicillin/streptomycin, 2 mM L-glutamine (Sigma-Aldrich, G7513) and 10% heat-inactivated fetal bovine serum (Sigma-Aldrich, F9665). Cells were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air. Under these conditions, pH of DMEM was about 7.7. For glutamine withdrawal experiments, cells were grown, for the time indicated, in complete medium without the addition of L-glutamine.

**Treatment protocols and antibodies**

Bafilomycin A1 (Sigma-Aldrich, B1793) was dissolved in Me2SO and added to a final concentration of 100 nM for the times indicated. BPTES (Sigma-Aldrich, SML0601) was dissolved in Me2SO and added to a final concentration of 10 μM for the times indicated. Hexachlorophene (Sigma-Aldrich, H4625) was dissolved in Me2SO and added to a final concentration of 5 μM for 24 h. Dimethyl-α-ketoglutarate was synthesized and provided by Prof. Mai and added to a 1 mM final concentration. Ammonium chloride (NH₄Cl) (Sigma Aldrich, A0171) was dissolved in water and added to a final concentration of 1, 2, or 10 mM for the indicated times. 2DG (Sigma Aldrich, D8375) was dissolved in water and added to a final concentration of 10 mM.

Antibodies used: SIRT5 (Abcam, 13697), MAP1LC3B (Novus Biologicals, NB600-1384), GABARAP and GABARAPL2 (MBL International Corporation, PM037 and PM038, respectively), SQSTM1 (Santa Cruz Biotechnology, sc-48402), BNI3P (Santa Cruz Biotechnology, sc-56167), MFN2 (Abnova, H00009927-M07), OPA1 (Novus Biologicals, H00004976-D01P), PINK1 (Santa Cruz Biotechnology, sc-33796), PARK2 (Santa Cruz Biotechnology, sc-32282), GLS (Novus Biologicals, H00002744-M01), GLUL (Novus Biologicals, H00002752-M02), GLUD1 (Santa Cruz Biotechnology, sc-160382), SIRT3 (Cell Signaling Technology, 2627), succinyl lysine (PTM-Biologs, PTM 419), acetylated lysine (Cell Signaling Technology, 9447), ACTB (Santa Cruz Biotechnology, sc-8432), COX4I1 (Santa Cruz Biotechnology, sc-69359).
Biochemical assays

Accumulation of lactate in the culture medium was determined using lactate assay kit II (Sigma-Aldrich, MAK065) according to the manufacturer’s protocol. ATP levels in cells were determined by using the ADP/ATP ratio assay kit (Sigma-Aldrich, MAK135) according to the manufacturer’s protocol. Glutamate levels in cell lines were determined by using the glutamate dehydrogenase activity assay kit (Sigma-Aldrich, MAK004) according to the manufacturer’s protocol. GLUD1 activity was determined by using the glutamate dehydrogenase solution was added. After 5 min absorbance was read at 340 nm in a Glomax multi detection system. In all measurements ammonia production in the absence of cells was subtracted from each experimental sample.

Ammonia-level assay

Ammonia levels in cell-conditioned medium was determined by using the ammonia assay kit (Sigma-Aldrich, AA0100) following the manufacturer’s protocol. Briefly, cells were grown for several days and medium was collected every other day. 100 µl of cell medium was mixed with 1 ml of ammonia assay reagent and incubated or 5 min at room temperature. Afterwards, 10 µl of glutamate dehydrogenase solution was added. After 5 min absorbance was read at 340 nm in a Glomax multi detection system. In all measurements ammonia production in the absence of cells was subtracted from each experiments.

Autophagic proteolysis assessment

Autophagic proteolysis of long-lived proteins was determined by using the Click-iT metabolic labeling for proteins (Life Technologies, C10428) according to the methodology of Zhang et al.72 Briefly, cells with 70% confluence were cultured in a 96-well plate (for fluorimeter measurements) or in a glass coverslip (for confocal microscopy). The day after cells were washed in phosphate buffered saline (PBS; Sigma-Aldrich, P4413) and then cultured in L-methionine-free medium for 2 h to deplete intracellular methionine reserves. Cells were then pulsed for 18 h with 50 µM Click-iT AHA (L-azidohomoalanine; Life Technologies, C10428) in methionine-free medium with 10% dialyzed fetal bovine serum to eliminate also this source of methionine. Afterward, cells were washed with PBS + 3% BSA (Sigma-Aldrich, A2153) and cultured for 2 h in complete medium containing methionine to chase out short-lived proteins. Cells then underwent various treatments as indicated in the figures legends. Starvation was achieved by incubating cells in amino acid free medium supplemented with 0.1% BSA and 2 mM L-methionine. Subsequently, cells were fixed in 4% paraformaldehyde for 15 min and permeabilized in 0.5% Triton X-100 (Sigma-Aldrich, T9284) for 20 min at room temperature. Finally cells were washed in PBS + 3% BSA. The detection click reaction was obtained by incubating fixed cells for 2 h with alkine-Alexa Fluor 488 (Life Technologies, C10428) in Click-iT cell reaction buffer kit. The reaction mixture was removed by washing samples with PBS + 3% BSA. Fluorescence from labeled long-lived proteins was measured using Glomax multidetection system. The fluorescence intensity of the assay buffer was subtracted from each experimental sample. Alternatively, fluorescence from labeled cells on the coverslips was observed using a LSM 510 confocal microscopy (Zeiss, 20020 Milan, Italy).

Docking protein-protein

The docking program Hex 6.137 has been used to evaluate possible interactions between SIRT5 and GLS. The X-ray structural coordinates of both SIRT5 and the catalytic domain of extract (5 µg) was incubated with the Fluor de Lys substrate buffer at 37°C for 1 h followed by incubation with Fluor de Lys Developer at 37°C for 40 min. After excitation at 360 nm, emitted light was detected at 460 nm using a Glomax multi detection system. The fluorescence intensity of the assay buffer was subtracted from each experimental sample.

SIRT5 inhibitor

Unless otherwise stated, in all experiments, cells were treated with 50 µM of SIRT5 inhibitor MC3482 for 24 h. The synthesis and characterization of MC3482 is reported in supplementary materials.

Generation of SIRT5-overexpressing and silenced stable transfectants

MDA-MB-231 and C2C12 cells were stably transfected with a pcDNA3.1 expression vector encoding human and mouse SIRT5-Flag (Addgene, 13816) for overexpression and for human SIRT5 and mouse Sirt5 shRNAs for silencing. Stable clones were generated by delivering plasmid DNA constructs into cells using TurboFectin 8.0 (Origene Technologies, TF81001) according to the manufacturer’s recommendations. Briefly, cells were seeded on a 24-well plate. The following day the cells were transfected. TurboFectin reagents were first mixed with serum-free RPMI at room temperature for 5 min. Subsequently, plasmid DNA was added to the TurboFectin-containing media and incubated at room temperature for 30 min. After that, the mixtures were added to the cells. The selection of stable overexpressing and silenced clones was started 24 h later with the addition of 500 µg/ml of geneticin (Sigma-Aldrich, A1720).

SIRT5 desuccinylating activity assay

SIRT5 desuccinylating activity was determined using a SIRT5 Fluorimetric Activity Assay/Drug Discovery Kit (Enzo Life Science, BML-AK513-0001) following the manufacturer’s protocol. In brief, the mitochondrial extract (5 µg) was incubated with the Fluor de Lys substrate buffer at 37°C for 40 min. followed by incubation with Fluor de Lys Developer at 37°C for 15 min. After excitation at 360 nm, emitted light was detected at 460 nm using Glomax multi detection system (Promega, 20137 Milan, Italy). The fluorescence intensity of the assay buffer was subtracted from each experimental sample.

SIRT1 and SIRT3 deacetylase activity assay

SIRT1 and SIRT3 deacetylase activity was determined using a SIRT1 or SIRT3 Fluorimetric Activity Assay/Drug Discovery Kit (Enzo Life Science, BML-AK555-0001 and BML-AK557-0001, respectively) following the manufacturer’s protocol. In brief, the whole (for SIRT1) or mitochondrial (for SIRT3)
human kidney GLS have been obtained from the Protein Data Bank database (www.pdb.org) with the ID codes: 3RIY and 3VOY, respectively.

A protein-protein docking analysis has been preformed with the GLS structure assembled into a tetramer. After adding the hydrogen atoms, removing the ligands and the water molecules, the molecular docking has been carried out using shape + electrostatics correlation mode, grid size of 0.4 Å to obtain 50000 solutions.46 The first high score 200 docking models were examined to choose the best interaction complex, taking into account the surface complementarity and the total energy of the complex. Inspection of the complexes was performed using the Chimera version 1.8 molecular graphics program.74 The complex chosen for the structural analysis shows a favorable value of protein-protein interaction energy of -242.3 kJ/mol.

**Protein extraction and western blot assay**

Cells (1 × 10⁶) for whole cell lysate were pelleted at 700 × g (5 min at 4°C) and lysed in 50 μl of cell lysis buffer (20 mM Tris, pH 7.4, 100 mM NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride [Sigma-Aldrich, P7626], 10 μg/ml leupeptin [Sigma-Aldrich, L9783], 10 μg/ml apro tin [Sigma-Aldrich, A3428]). After 30 min on ice, the lysates were clarified by centrifugation (10 min at 4°C) and the supernatant fraction was collected. Protein concentration was determined by Bradford assay (Bio-Rad, 500-0002). Equivalent amounts of protein were electrophoresed on SDS-polyacrylamide gels. Kaleidoscope Prestained Standards (Bio-Rad, 161-0375) were used to determine molecular weight. The gels were then electroblotted onto PVDF (Bio-Rad, 162-0219) membranes. After blocking with 5% milk, membranes where incubated with the primary antibody overnight. Finally, the relevant protein was visualized by staining with the appropriate secondary horseradish peroxidase-labeled antibody for 1 h followed by enhanced chemiluminescence. Densitometric analysis of the bands, relative to ACTB of COX4I1, was performed using Image J software (National Institutes of Health).

**Mitochondria isolation**

Cells (2 × 10⁶) were plated in 100 mm dishes. Following treatment the cells were scraped off the plate using a rubber policeman and centrifuged at 700 × g for 10 min at 4°C. The cell pellets were resuspended in 1 ml of 20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, 10 μg/ml apro tin, and 250 mM sucrose (Sigma-Aldrich, S9378). The cells were broken open with 6 passages through a 26-gauge needle applied to a 1-ml syringe. The homogenate was centrifuged at 1000 g for 5 min at 4°C. The supernatant fraction was transferred to a high-speed centrifuge tube and centrifuged at 10,000 g for 25 min at 4°C. The pellet (mitochondrial) fraction was lysed in 50 mM Tris [tris(hydroxymethyl)aminomethane]–HCl, 150 mM NaCl, 1% Triton X-100, 0.1% Nonidet P-40 (Sigma-Aldrich, 74388), 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, 10 μg/ml apro tin. Protein concentration of the fraction was determined by the Bradford assay (Bio-Rad).

The purity as well as equal loading of mitochondrial fraction was determined by measuring levels of mitochondrial protein COX4I1.

**Electron microscopy**

MDA-MB-231 cells were trypsinized and pelleted. The cells were then suspended and fixed overnight at 4°C in 2% glutaraldehyde with 1% tannic acid in 0.1 M sodium cacodylate, pH 7.3. The cells were rinsed 3 times in the sodium cacodylate buffer and then incubated in 2% osmium tetroxide in the same buffer for 2 h at room temperature. The cells were then rinsed 3 times in distilled water and exposed to 1% uranyl acetate in water for 15 min at room temperature. The cells were rinsed twice in distilled water, spun down into 3% agarose at 45°C, and cooled to form blocks. The agarose blocks were dehydrated in graded steps of acetone and embedded in Spur's low viscosity media. Following polymerization overnight at 65°C, 80-nm sections were cut on a Reighert-Jung Ultra cut E ultramicrotome (Leica Microsystems, 20132 Milan, Italy) and picked up on copper grids. The grids were post-stained in uranyl acetate and bismuth subnitrate. The sections were observed in a Philips CM-10 TEM (FEI Italia, 20122 Milan, Italy) and micrographs recorded on Kodak 4489 sheet film.

**PEG fusion assay**

Forty thousand cells labeled with Mitotracker Green (40 nM; Life Technologies, M7514) were cultured overnight on 25-mm coverslips with 40,000 cells labeled with Mitotracker Red (10 nM; Life Technologies, M22426). The next morning, cells were fused for 60 s with 50% PEG 1500 (Roche, 10783641001). The cells were washed and grown for 7 h in growth medium. Afterwards, coverslips were visualized in a LSM 510 confocal microscopy (Zeiss).

**Mitochondria staining and determination of the ΔΨₘt**

Mitochondrial morphology and membrane potential (ΔΨₘt), were analyzed by using the ΔΨₘt sensitive dye 5,5',6,6'-tetra-chloro-1',3',3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) (Life Technologies, T3168). Cells (1 × 10⁶) were cultured on 25-mm coverslips placed in a 6-well plate. The day after, cells were incubated in fresh media containing 10 μM JC-1 for 15 min at 37°C. After 2 washes in PBS to remove the excess of JC1, cell staining was determined by analysis on a LSM 510 confocal microscopy (Zeiss).

**Immunoprecipitation assay**

Proteins were extracted as mentioned above. After determining protein concentration using the Bradford assay, 500 μg of the lysate was brought to a final volume of 1 ml with PBS. Lysates were precleared with 1 μg of appropriate control IgG (Santa Cruz Biotechnology, sc-2763) and 20 μl of protein A/G PLUS-agarose (Santa Cruz Biotechnology, sc-2003) and kept on a rotator for 1 h at 4°C. Lysates were centrifuged (500 × g for 5 min at 4°C) and 2 μg of GLS, SIRT5 or GLUD1 antibody or corresponding IgG was added to the precleared lysates and kept on ice for approximately 3 to 5 h. Following incubation, 30 μl
of protein A/G PLUS-agarose was added to each tube and kept on a rotator overnight at 4°C. Lysates were then centrifuged (500 × g for 5 min at 4°C). The pellet fractions were washed 4 times with PBS and then resuspended in 20 μl of loading buffer. Samples were electrophoresed on an 8% SDS-polyacrylamide gel and immunoblotted with the appropriate antibody as indicated in the figures.

Statistical analysis

The results are expressed as means ± standard deviations (s.d.) and 95% confidence intervals (95% CI). Before using parametric tests, the assumption of normality was verified using the Shapiro-Wilk W-test. The Student paired t test was used to determine any significant differences before and after treatment. Significance was set at 0.05 (P ≤ 0.05). SPSS statistical software package (SPSS Inc., Version 13.0.1 for Windows Chicago, IL, USA) was used for all statistical calculations.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1 Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069-75; PMID:18305538; 10.1038/nature06639
2 Nakahira K, Cleonan SM, Mizumura K, Choi AM, Ryter SW. Autophagy: a crucial moderator of redox balance, inflammation, and apoptosis in lung disease. Antioxid Redox Signal 2014; 20:474-94; PMID:23879400; http://dx.doi.org/10.1089/ars.2013.5373
3 Di Bartolomeo S, Corazzari M, Nazio F, Oliverio S, Lisi G, Antonioli M, Pagliarini V, Mattroini S, Fucito C, Giunta L, et al. The dynamic interaction of ABMA1 with the dynein motor complex regulates mammalian autophagy. J Cell Biol 2010; 191:155-68; PMID:20892453; http://dx.doi.org/10.1083/jcb.201002100
4 Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol-3-kine complexes with mammalian Arg14 and UVRAG. Mol Biol Cell. 2008; 19:5360-72; PMID:18843052; http://dx.doi.org/10.1091/mbc.E08-01-0080
5 Kubli DA, Gustafsson A. Mitochondria and mitophagy: the Yin and Yang of cell death control. Circ Res. 2012; 111:1208-21; PMID:23565344; http://dx.doi.org/10.1161/CIRCRESAHA.112.265819
6 Chan EY, Longatti A, McKnight NC, Toozee SA. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Arg13-independent mechanism. Mol Cell Biol 2009; 29:157-71; PMID:18936157; http://dx.doi.org/10.1128/MCB.01082-08
7 Nakagawa T, Guarente L. Sirrius at a glance. J Cell Sci 2011; 124:833-8; PMID:21378304; http://dx.doi.org/10.1242/jcs.081067
8 Merkamer PI, Liu Y, He W, Hirschy MD, Chen D, Verdin E. The sirrius, oxidative stress and aging: an emerging link. Aging (Albany NY). 2013; 5:144-50; PMID:23474711
9 Sato BA, Youn DY. Sirrius: NAD(+)-dependent deacetylation mechanism and regulation.Curr Opin Chem Biol 2012; 16:535-43; PMID:23102634; http://dx.doi.org/10.1016/j.cbpa.2012.10.003
10 Radak Z, Kolzi E, Taylor AW, Higuchi M, Kumagai S, Ohno H, Goto S, Böldgh I. Redox-regulating sirrius in aging, caloric restriction, and exercise. Free Radic Biol Med 2013; 58:887-97; PMID:23398850; http://dx.doi.org/10.1016/j.freeradbiomed.2013.01.004
11 Sack MN, Finkel T. Mitochondrial metabolism, sirrius, and aging. Cold Spring Harb Perspect Biol 2012; 4 (12); PMID:23209156
12 Lee HI, Cao L, Marynych V, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T. A role for the NAD-dependent deacetylase Sir2l in the regulation of autophagy. Proc Natl Acad Sci U S A 2008; 105:3574-9; PMID:18296641; http://dx.doi.org/10.1073/pnas.0712134105
13 Nezis IP, Stenmark H. p62 at the interface of autophagy, oxidative stress signaling, and cancer. Antioxid Redox Signal 2012; 17:786-93; PMID:22074114; http://dx.doi.org/10.1089/ars.2011.4994
14 Dairaku H, Sakamaki J, Fukumitsu A. Regulator of Fox transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 2011; 1813:1954-60; PMID:21396404; http://dx.doi.org/10.1016/j.bbamcr.2011.03.001
15 Kanamori H, Takekura G, Goto K, Tsujimoto A, Morishita K, Kawasaki M, et al. Resveratrol reverses Sirt5-mediated degradation of protein aggregates in neuronal cells under proteasome inhibition. Neurochem Int. 2012; 61:992-1000; PMID:22819792; http://dx.doi.org/10.1016/j.neuroint.2012.07.010
19 Chen ML, Yi L, Xu X, Liang XY, Zhou Y, Zhang T, Xie Q, Zhou X, Chang H, Fu YJ, et al. Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy 2013; 9:2033-45; PMID:24145604; http://dx.doi.org/10.4265/auto.2013.07.002
20 Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L, Zha WG. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2012; 11:1381-91; PMID:22819792; http://dx.doi.org/10.1016/j.neuroint.2012.07.010
21 Pernetti A, Bert M, Fernández-Valle C. Inhibition of SIRT2 in melanoma cells triggers necroinflammation. Oncotarget 2013; 4:2354-45; PMID:24529290
23 Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthase 1 and regulates the urea cycle. Cell 2009; 137:750-60; PMID:19410549; http://dx.doi.org/10.1016/j.cell.2009.02.026
26 Tan M, Peng C, Anderson KA, Chhoy P, Xie Z, Dai L, Park J, Chen Y, Huang H, Zhang Y, et al. Lysine glutaryl-RNA is a protein posttranslational modification regulated by SIRT5. Cell Metab 2014; 19:605-17; PMID:24705039; http://dx.doi.org/10.1016/j.cmet.2014.03.014
27 Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, Guo A, Gut P, Sahu AK, Li B, et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab 2013; 18:2030-33; PMID:24318375; http://dx.doi.org/10.1016/j.cmet.2013.11.013

Acknowledgments

Authors wish to thank M. Falconi for his help with the protein-protein docking analysis and S. Ilari for her help with the glutamate measurements.

Funding

This work was partially supported by the Italian Space Agency grant DC-DTE-2011-2013, by FIRB RBFR10QJT, Sapienza Ateneo Project 2013, IIT-Sapienza Project, FP7 Project BLUE-PRINT/282510, by PRIN 2012 (prot. 2012 CTASYS) and by PRIN 2010-2011 (prot. 2010 S7CT4_004). This work was also supported by BMBF grant ProNet-T3 to M. Schutkowski.

Supplemental Material

Supplemental data for this article can be accessed on the publisher’s website.

www.tandfonline.com
Autophagy
269
Cassago A, Ferreira AP, Ferreira IM, Fornezari C, Gomes Wise DR, Thompson CB. Glutamine addiction: a new regulator of autophagy. Sci Signal 2010; 3:ra31; http://dx.doi.org/10.1126/sci信号.1073.1014.

Eng CH, Yu K, Lucas J, White E, Abraham RT. Mitochondrial localization and structure-function of glutaminolysis and cell biology and cancer. Proc Natl Acad Sci U S A 2011; 108:11121-6; PMID:21690395; http://dx.doi.org/10.1073/pnas.1107969108.

Chen R, Driver C, Boulter EJ. Yma1p: The next of the diverse functions of glutaminase in metabolism, cell biology and cancer. Oncogene 2010; 29:3123-34; PMID:20881548; http://dx.doi.org/10.1038/onc.2009.358.

Casagauo A, Ferreira AP, Ferreira IM, Fornezari C, Gomes Wise DR, Thompson CB. Glutamine addiction: a new regulator of autophagy. Sci Signal 2010; 3:ra31; http://dx.doi.org/10.1126/sci信号.1073.1014.

DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Ambrosio AL. Mitochondrial localization and structure-function of glutaminolysis in metabolism, cell biology and cancer cells: a druggable chain of events. Drug Discov Today 2014; 19:450-7.

DeBerardinis RJ, Daikhin E, Nissim I, Ambrosio AL. Mitochondrial localization and structure-function of glutaminolysis in metabolism, cell biology and cancer cells: a druggable chain of events. Drug Discov Today 2014; 19:450-7.

DeBerardinis RJ, Daikhin E, Nissim I, Ambrosio AL. Mitochondrial localization and structure-function of glutaminolysis in metabolism, cell biology and cancer cells: a druggable chain of events. Drug Discov Today 2014; 19:450-7.

Thompson CB. Glutamine addiction: a new regulator of autophagy. Sci Signal 2010; 3:ra31; http://dx.doi.org/10.1126/sci信号.1073.1014.

Veske M, Vesterlund J, Draper J, et al. The role of glutaminase and glutamine synthetase in the control of the glutamine-arginine axis. Proc Natl Acad Sci U S A 2009; 106:20475-50; PMID:19919167; http://dx.doi.org/10.1073/pnas.0901184106.

Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci 2013; 104:275-81; PMID:23279494; http://dx.doi.org/10.1111/cas.12085.

Kart WP, Cerione RA. Glutamine regulation in cancer cells: a drug target in cancer. Drug Discov Today 2014; 19:450-7.